AEWS0031
AEWS0031 showed that giving the same chemotherapy for Ewing sarcoma every two weeks instead of every three cured more patients without adding side effects, and the two-weekly schedule became the standard for localised disease in North America.
Overview
AEWS0031 was a Children's Oncology Group phase 3 trial that randomised 587 patients (568 eligible, 284 per arm) with localised Ewing sarcoma to fourteen cycles of alternating vincristine, doxorubicin, cyclophosphamide and ifosfamide, etoposide given every 21 days or every 14 days with growth factor support. The primary endpoint was event-free survival.
The median cycle interval achieved was 21 days in the standard arm and 15 days in the intensified arm. Event-free survival at five years was 73 percent with interval compression against 65 percent with the standard schedule, with similar toxicity. Interval-compressed VDC/IE is the standard first-line regimen on the corpus's Ewing sarcoma page, alongside the European Euro Ewing 2012 result that reached the same conclusion.
- 73 vs 65 out of 100 free of a major event at 5 years with Interval-compressed VDC/IE every 14 days compared with Standard VDC/IE every 21 days; 8 more per 100.
- Roughly one extra person helped for every 13 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- The p-value (0.048) says a difference this large would rarely happen by chance; it does not say how large or how useful the difference is.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Localised Ewing sarcoma in patients under 50: fourteen cycles of alternating vincristine, doxorubicin and cyclophosphamide with ifosfamide and etoposide given every three weeks (standard) or every two weeks with filgrastim support (interval-compressed), around local control with surgery or radiotherapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
587 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival at 5 yearsprimary | Interval-compressed VDC/IE every 14 days | 284 | 73% | - | 0.048 | link |
| Standard VDC/IE every 21 days | 284 | 65% |
Similar pages
not linked directly; found by shared links- TrialEuroNet-PHL-C2
Shares Childhood cancers (all types), Vincristine, Etoposide, Cyclophosphamide and the tag soc-trials.
- TrialANBL17P1
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.
- TrialAHOD1331
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.
- TrialACNS0121
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.
- TrialANBL0531
Shares Childhood cancers (all types), Children's Oncology Group (COG), Etoposide, Cyclophosphamide and the tag soc-trials.
- TrialACNS1123
Shares Ifosfamide, Childhood cancers (all types), Children's Oncology Group (COG), Etoposide and the tag soc-trials.
- TrialACNS1422
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag soc-trials.
- TrialACNS0333
Shares Childhood cancers (all types), Children's Oncology Group (COG), Vincristine, Etoposide and the tag soc-trials.